European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

First ever preventive treatment for celiac disease and gluten sensitivity

Cel

E40 is a novel gluten degrading enzyme aimed at enhancing the degradation of ingested gluten, particularly in gluten intolerant Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) sufferers.

Different from any other competing enzymes under development, E40 efficiently exerts its gluten degrading activity in both the stomach and the intestine of CeD and NCGS sufferers, supporting the benefits of a Gluten Free Diet (GFD). The final goal is to prevent symptomatology due to the pro-inflammatory reaction triggered by gluten.

E40 will allow sufferers to manage inadvertent gluten exposure and will improve sufferer's Quality of Life, in particular allowing them to normalise their work and social life, reducing anxiety and allowing them to enjoy many everyday activities, like eating in a restaurant, travelling and visiting their friends in their homes.

E40 is produced by an engineered, patented acidic Streptomyces lividans TK24 strain, and directly purified in its mature, functional form. E40 activity has already been confirmed using the validated human simulated digestion INFOGEST assay of real food digestion: E40 gluten degradation leads to a gluten-free status (residual gluten<20ppm as per EC guidelines).

Koordynator

NEMYSIS LIMITED
Wkład UE netto
€ 2 499 999,00
Adres
SUITE 4 01 ORMOND BUILDING 31-36 ORMOND QUAY UPPER
D07 F6DC DUBLIN
Irlandia

Zobacz na mapie

MŚP

Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.

Tak
Region
Ireland Eastern and Midland Dublin
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
€ 4 243 109,69